Mechanisms of early Recurrence in Intracranial Atherosclerotic Disease (MyRIAD): Rationale and design.
Adult
Brain Infarction
/ diagnostic imaging
Cerebrovascular Circulation
Female
Humans
Intracranial Arteriosclerosis
/ complications
Ischemic Attack, Transient
/ diagnostic imaging
Magnetic Resonance Angiography
Male
Middle Aged
Predictive Value of Tests
Prospective Studies
Recurrence
Research Design
Risk Factors
Time Factors
Ultrasonography, Doppler, Transcranial
Biomarkers
Intracranial arterial disease
Research design
Stroke
Journal
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
ISSN: 1532-8511
Titre abrégé: J Stroke Cerebrovasc Dis
Pays: United States
ID NLM: 9111633
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
04
05
2020
revised:
08
06
2020
accepted:
09
06
2020
entrez:
11
9
2020
pubmed:
12
9
2020
medline:
11
11
2020
Statut:
ppublish
Résumé
Intracranial atherosclerotic disease (ICAD) is the most common cause of ischemic stroke with the highest rate of recurrence, despite aggressive medical management. Diverse mechanisms may be responsible for ICAD-related cerebral ischemia, with potential therapeutic implications. Here we present the rationale, design and methods of the Mechanisms of Early Recurrence in Intracranial Atherosclerotic Disease (MyRIAD) study. The aim of MyRIAD is to determine the mechanisms of stroke in ICAD through physiologic imaging biomarkers that evaluate impaired antegrade flow, poor distal perfusion, abnormal vasoreactivity, artery to artery embolism, and their interaction. This is a prospective observational study of patients with recently symptomatic (<21 days) ICAD with 50-99% stenosis treated medically and monitored for up to 1 year. An estimated 110 participants are recruited at 10 sites to identify the association between the presence of each mechanism of ischemia and recurrent stroke. The primary outcome is ischemic stroke in the territory of the symptomatic artery. Secondary outcomes include new cerebral infarction on MRI at 6-8 weeks and recurrent TIA in the territory of the symptomatic artery. MyRIAD is positioned to define the role of specific mechanisms of recurrent ischemia in patients with symptomatic ICAD. This knowledge will allow the development and implementation of effective and specific treatments for this condition.
Identifiants
pubmed: 32912558
pii: S1052-3057(20)30469-9
doi: 10.1016/j.jstrokecerebrovasdis.2020.105051
pmc: PMC7490766
mid: NIHMS1605166
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
105051Subventions
Organisme : NINDS NIH HHS
ID : R01 NS084288
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.
Références
Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):e51-60
pubmed: 22991350
JAMA. 2000 Apr 26;283(16):2122-7
pubmed: 10791504
JAMA Neurol. 2016 Feb;73(2):178-85
pubmed: 26720181
Lancet. 2014 Jan 25;383(9914):333-41
pubmed: 24168957
N Engl J Med. 2011 Sep 15;365(11):993-1003
pubmed: 21899409
Stroke. 2008 Aug;39(8):2396-9
pubmed: 18535283
AJNR Am J Neuroradiol. 2007 Sep;28(8):1470-3
pubmed: 17846193
Curr Neurovasc Res. 2017;14(2):149-157
pubmed: 28412909
JAMA. 2015 Mar 24-31;313(12):1240-8
pubmed: 25803346
AJNR Am J Neuroradiol. 2000 Apr;21(4):643-6
pubmed: 10782772
Stroke. 2005 Jun;36(6):1140-5
pubmed: 15890993
Cerebrovasc Dis. 2014;37(3):203-11
pubmed: 24557055
Stroke. 2004 Dec;35(12):2832-6
pubmed: 15514175